0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

TOXIC REACTIONS OF PAREDRINE-SULFATHIAZOLE SUSPENSION:  REPORT OF TWO CASES

Merrill C. O'Donnell, M.D.
JAMA. 1943;122(5):298. doi:10.1001/jama.1943.72840220003007a.
Text Size: A A A
Published online

ABSTRACT

As this new drug has been presented to the medical profession, it is desirable that any untoward reactions from it be brought to the immediate attention of the physician.

Paredrine-sulfathiazole suspension is a preparation introduced by the Smith, Kline and French Pharmaceutical Company. The active components are a suspension of microcrystal sulfathiazole 5 per cent in an isotonic solution of 1 per cent paredrine hydrobromide (p-hydroxy-a-methylphenethylamine). The preservative used is sodium ethyl mercuri thiosalicylate 0.005 per cent; gelatin is present in 0.1 per cent. The product has been recommended by its makers as a vasoconstrictor of the nasal mucosa, with the additional value of the antibacteriostatic action of sulfathiazole. It may be introduced into the nasal cavity and sinuses by drops, atomizer or the displacement method of Proetz. The cases under study have been treated at the Otolaryngological Clinic of the St. Louis University Group of Hospitals.

Case 1.—  C.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();